This trial is evaluating whether Secukinumab will improve 1 primary outcome and 1 secondary outcome in patients with Psoriasis. Measurement will happen over the course of 52 weeks.
This trial requires 196 total participants across 5 different treatment groups
This trial involves 5 different treatments. Secukinumab is the primary treatment being studied. Participants will be divided into 4 treatment groups. There is no placebo group. The treatments being tested are in Phase 4 and have been shown to be safe and effective in humans.
"Around 2 million people are affected by psoriasis in the United States a year. About 12 percent have plaque-type plaques and the remaining 88 percent have linear, joint-type plaques. The majority of patients have experienced psoriasis for many years." - Anonymous Online Contributor
"The most common treatments for psoriasis in this European population included topical corticosteroids, oral immunosuppressive therapy, and ustekinumab. Psoriasis in children and adolescents does not appear to generally require specific treatment because of its rarity. Psoriasis is not treatable and therefore requires constant observation of severity of itchiness, skin disease, nail deformities, and disease progression. Clinicians should maintain long-term follow up of cases of this common and challenging skin disease both in the primary and tertiary care." - Anonymous Online Contributor
"The most common symptom is plaques at the edges of the fingernails, which may be followed by scaling and cracking. Other typical symptoms include dry nails and hyperpigmentation. Other manifestations of psoriasis are hyperkeratosis, pustules, and inflamed lymph nodes, as well as red skin. Psoriasis can appear after infancy or later on in life." - Anonymous Online Contributor
"There is an increasing amount of anecdotal reports about remission with the usage of immunosuppressive drugs such as corticosteroids, biologics and synthetic analogues. There is one controlled trial with 1 patient. The authors have also recently published their experience with a case of systemic chemotherapy. Recently 3 trials have shown remission with biologics. However, there are no clear guidelines about how to treat psoriasis. What can be safely recommended is to take a thorough medical history and do regular full skin examination which can reveal what's wrong with the skin. In order to find out what's really wrong with the skin, we, dermatologists, prescribe drugs and ask the patient to visit us every month and tell us the result." - Anonymous Online Contributor
"A high level of knowledge and education among psoriasis patients is very important to minimize the consequences of the disease and the need for prescription drugs, medical procedures, and hospital stays. Psoriasis is an allergic-immunological, systemic disease and it has no known cure. Psoriasis is characterized by skin lesions. These lesions contain red blood cell-filled plaques and a thickened layer of skin that can cause itching, loss of scalp of hair, and bleeding from the skin when cut. Psoriasis may cause depression. Psoriasis is not a chronic skin disease, but a skin condition that occurs and subsides as time passes. There are different types of psoriasis, none of which can be cured." - Anonymous Online Contributor
"While the cause of psoriasis is not well understood, we propose the first biological plausibility of a model of causation in atopic dermatitis (eczema) and psoriasis and discuss potential drug therapies." - Anonymous Online Contributor
"Patients treated with secukinumab+ methotrexate experienced significant improvement in psoriasis symptoms. However, patients treated with secukinumab+ methotrexate+ etanercept reported more improvement in skin lesions than those treated with secukinumab+ etanercept." - Anonymous Online Contributor
"The majority of the publications and marketing reports refer generally to a combination with methotrexate, but there are already a lot of publications and marketing reports regarding Secukinumab monotherapy as an orphan drug, especially in USA. This might be caused by the fact that Secukinumab has a different development strategy than that of biosimilar drugs." - Anonymous Online Contributor
"Patients with erythema nodosum in the hands receiving adalimumab for psoriatic arthritis are more likely to experience improvement in the signs and symptoms of psoriasis than patients receiving placebo. Treatment-related adverse events seem to be more common with secukinumab than with adalimumab." - Anonymous Online Contributor
"Commonly reported adverse events (≥1% patients) with secukinumab occurred frequently (<10% for total patients) at the beginning of therapy and are not anticipated, based on the frequency of such adverse effects in patients treated using other anti-IL-12/23 agents in early phase 2 trials performed in patients with psoriasis who were naïve to anti-IL-12/23 treatments." - Anonymous Online Contributor
"If a patient was to have a skin biopsy, I would urge a histopathologist to go to see the tissue and discuss the lab results with the patient before ordering skin tests to see if autoimmunity is present. If autoimmunity appears, the patient should be tested for rheumatoid arthritis because psoriasis is very similar to rheumatoid osteoarthropathy and the two may also share common genetic risk factors." - Anonymous Online Contributor
"In this global, prospective, multi-arm trial, Secukinumab reduced the extent of psoriasis, improved the disease burden and improved the quality of life in people with moderate to severe psoriasis. Findings from a recent study support the use of secukinumab in psoriasis." - Anonymous Online Contributor